data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Lumos Pharma

(NASDAQ:LUMO)

Intraday

$2.88

0.11[3.97%]

After-Hours

$2.88

0[0.00%]

Perks Buy Compare Brokers

$2.88

0.11[3.97%]

At close: Apr 24

$2.88

0[0.00%]

PreMarket: 9:27AM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Lumos Pharma Stock (NASDAQ:LUMO)

Lumos Pharma Stock (NASDAQ: LUMO)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 18, 2024

Lumos Pharma Announces Abstracts Reviewing Data From Its Phase 2 OraGrowth210 And OraGrowth212 Trials Will Be Presented At Upcoming Medical Meetings
Benzinga Newsdesk - Apr 18, 2024, 4:08PM

Wednesday, March 20, 2024

HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Mar 20, 2024, 12:29PM
Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
Benzinga Newsdesk - Mar 20, 2024, 8:06AM

Friday, March 08, 2024

Oppenheimer Maintains Outperform on Lumos Pharma, Maintains $16 Price Target
Benzinga Newsdesk - Mar 8, 2024, 9:04AM
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Mar 8, 2024, 6:52AM

Thursday, March 07, 2024

Lumos Pharma: Q4 Earnings Insights
Benzinga Insights - Mar 7, 2024, 4:10PM
Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate
Benzinga Newsdesk - Mar 7, 2024, 4:09PM
Earnings Scheduled For March 7, 2024
Benzinga Insights - Mar 7, 2024, 4:49AM

Wednesday, March 06, 2024

Earnings Preview: Lumos Pharma
Benzinga Insights - Mar 6, 2024, 1:01PM

Monday, December 11, 2023

Oppenheimer Maintains Outperform on Lumos Pharma, Lowers Price Target to $16
Benzinga Newsdesk - Dec 11, 2023, 10:21AM

Thursday, December 07, 2023

HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Dec 7, 2023, 6:43AM

Tuesday, November 21, 2023

Lumos Pharma To Host Virtual Key Opinion Leader Webinar To Discuss Phase 2 OraGrowtH Trial Data And Treatment Potential Of Oral LUM-201 For Pediatric Growth Hormone Deficiency
Benzinga Newsdesk - Nov 21, 2023, 4:29PM

Wednesday, November 08, 2023

Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Nov 8, 2023, 1:41PM
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
Vandana Singh - Nov 8, 2023, 1:20PM
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
Lisa Levin - Nov 8, 2023, 11:02AM
Market-Moving News for November 8th
Benzinga Newsdesk - Nov 8, 2023, 8:42AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Nov 8, 2023, 8:06AM
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Nov 8, 2023, 7:49AM

Tuesday, November 07, 2023

Lumos Pharma Q3 EPS $(1.04) Beats $(1.15) Estimate, Sales $7.00K Miss $320.00K Estimate
Benzinga Newsdesk - Nov 7, 2023, 5:05PM
Lumos Pharma Announces Topline Data From Phase 2 OraGrowtH210 And OraGrowtH212 Trials Of LUM-201 In PGHD Met All Primary And Secondary Endpoints
Benzinga Newsdesk - Nov 7, 2023, 5:05PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - Nov 7, 2023, 4:31PM

Monday, October 30, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Oct 30, 2023, 9:05AM

Tuesday, September 26, 2023

Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting
Benzinga Newsdesk - Sep 26, 2023, 9:20AM

Wednesday, September 06, 2023

What 7 Analyst Ratings Have To Say About Lumos Pharma
Benzinga Insights - Sep 6, 2023, 9:00AM
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Sep 6, 2023, 6:30AM

Tuesday, August 22, 2023

Cantor Fitzgerald Reiterates Overweight on Lumos Pharma, Maintains $10 Price Target
Benzinga Newsdesk - Aug 22, 2023, 9:55AM

Tuesday, August 15, 2023

The Latest Analyst Ratings for Lumos Pharma
Benzinga Insights - Aug 15, 2023, 1:00PM
Cantor Fitzgerald Maintains Overweight on Lumos Pharma, Lowers Price Target to $10
Benzinga Newsdesk - Aug 15, 2023, 8:11AM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Oppenheimer Maintains Outperform on Lumos Pharma, Lowers Price Target to $17
Benzinga Newsdesk - Aug 10, 2023, 11:49AM
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Aug 10, 2023, 6:35AM

Wednesday, August 09, 2023

Lumos Pharma Q2 EPS $(1.09) Beats $(1.10) Estimate, Sales $527.00K Beat $410.00K Estimate
Benzinga Newsdesk - Aug 9, 2023, 4:21PM
Earnings Scheduled For August 9, 2023
Benzinga Insights - Aug 9, 2023, 4:54AM

Monday, July 24, 2023

Cantor Fitzgerald Reiterates Overweight on Lumos Pharma, Maintains $14 Price Target
Benzinga Newsdesk - Jul 24, 2023, 9:54AM

Thursday, June 29, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights - Jun 29, 2023, 1:37PM

Thursday, June 22, 2023

HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Jun 22, 2023, 6:07AM

Wednesday, June 21, 2023

Lumos To Highlight New LUM-201 Data And Analysis Presented At ENDO 2023 In Virtual KOL Webinar
Happy Mohamed - Jun 21, 2023, 9:15AM

Monday, May 08, 2023

Data From Lumos Pharma OraGrowtH Trials Presented At Annual Pediatric Endocrine Society Meeting
Happy Mohamed - May 8, 2023, 8:05AM

Thursday, May 04, 2023

HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - May 4, 2023, 6:38AM

Wednesday, May 03, 2023

Lumos Pharma: Q1 Earnings Insights
Benzinga Insights - May 3, 2023, 4:20PM
Lumos Pharma Q1 EPS $(0.89) Beats $(1.12) Estimate, Sales $691.00K Beat $180.00K Estimate
Benzinga Newsdesk - May 3, 2023, 4:15PM

Monday, April 03, 2023

Lumos Pharma Sponsored Trial A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial Posted To Clinical Trials Website; Not yet recruiting
Charles Gross - Apr 3, 2023, 12:19PM

Monday, March 06, 2023

HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga Newsdesk - Mar 6, 2023, 10:52AM

Sunday, March 05, 2023

Lumos Pharma Announced Oral Presentation Highlighting Data On 15 Subjects From OraGrowtH212 Trial Supportive Of Conclusions From Interim Data Analysis
Charles Gross - Mar 5, 2023, 2:46PM

Wednesday, March 01, 2023

Lumos Pharma Q4 EPS $(0.98) Misses $(0.93) Estimate, Sales $512.00K Beat $110.00K Estimate
Benzinga Newsdesk - Mar 1, 2023, 4:09PM
Earnings Scheduled For March 1, 2023
Benzinga Insights - Mar 1, 2023, 6:59AM

Tuesday, February 28, 2023

Lumos Pharma Completes Patient Enrollment In Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 In Moderate Idiopathic PGHD
Happy Mohamed - Feb 28, 2023, 4:49PM
A Preview Of Lumos Pharma's Earnings
Benzinga Insights - Feb 28, 2023, 1:00PM

Monday, December 26, 2022

Lumos Pharma Earnings Perspective: Return On Capital Employed
Benzinga Insights - Dec 26, 2022, 9:47AM

Monday, December 12, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 12, 2022, 10:50AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved